Clinical Guidelines

Romiplostim May Improve Chemotherapy-Induced Thrombocytopenia in Patients With GI Cancers

Romiplostim was beneficial in treating chemotherapy-induced thrombocytopenia, according to findings from the global phase III RECITE trial published in The New England Journal of Medicine.  

Share

  • 1

    Romiplostim is studied for chemotherapy-induced thrombocytopenia.

  • 2

    The RECITE trial was double-blind and placebo-controlled.

  • 3

    165 patients with gastrointestinal cancers were enrolled.

  • 4

    84% of romiplostim patients had no dose modifications.

  • 5

    Common adverse events included nausea and headache.

  • 6

    No deaths or treatment discontinuation linked to adverse events.

  • 7

    Significant improvement in maintaining chemotherapy dose is vital for patient outcomes.

Original Source(s)

Romiplostim May Improve Chemotherapy-Induced Thrombocytopenia in Patients With GI Cancers

  • by The ASCO Post Staff

  • March 17, 2026

Related Content

Targeted NGS Streamlines Myeloproliferative Neoplasm Diagnostics

Kritika Krishnamurthy shares real-world experience on advanced MPN genomic profiling

  • March 18, 2026

  • 9 min
Register Today for Roswell Park’s Upstate New York Hematology & Hematologic Oncology Conference

Register for the Upstate New York Hematology & Hematologic Oncology Conference: A Review of the 67th ASH Annual meeting, taking place on April 25-26 in Buffalo, NY.

  • by

  • March 13, 2026

  • 1 min
Enhancing Immune Thrombocytopenia Education and Support: Insights From a Learning Exchange Program